Thermobalancing therapy helps improve type-III CP/CPPS
Thermobalancing therapy (TT) appears to be an effective treatment for type-III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), the most common type of prostatitis, suggests a recent study.
Furthermore, 6-month TT using Dr Allen’s therapeutic device (DATD) reduces CP/CPPS symptoms and improves quality of life (QoL), reduces prostatic volume, and increases maximum urinary flow rate.
To determine the effect of TT using DATD on CP/CPPS, the investigators measured National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) scores, prostatic volume and maximum urinary flow rate in a cohort of patients (n=45) who underwent TT and a control group that did not have TT. Then, they compared the parameters between the two groups.
Based on baseline evaluation of both groups, there was no significant difference with regard to age, NIH-CPSI score, prostatic volume or maximum urinary flow rate. The two groups both showed a reduction in pain score. However, the difference between scores was significantly higher (8.72:1) in the treatment group than that in the nontreatment group.
QoL decreased significantly with TT, but in the control group there was just a slight decrease in QoL. TT markedly reduced prostatic volume, while in the control group prostatic volume increased. Moreover, TT increased maximum urinary flow rate in CP/CPPS patients, but it did not deliver a significant change in maximum urinary flow rate among those in the control group.
In another study, researchers found that TT with DATD is effective for benign prostatic hyperplasia, suggesting that blood circulation plays a crucial role in its cause. [Aging Male 2017;20:28-32]